洛铂对比顺铂同步放射治疗ⅡB-ⅣA期宫颈癌的疗效及毒副反应  

Comparison of efficacy and toxicity in lobaplatin-based and cisplatin-based concurrent chemoradiotherapy for StageⅡB-ⅣA cervical cancer

作　　者：林远雄[1] 杨廉洲 陈戈 郭康文 LIN Yuan-xiong;YANG Lian-zhou;CHEN Ge;GUO Kang-wen(Tumor Radiotherapy Department,Central Hospital of Guangdong Nongken,Zhanjiang 524002,China)

机构地区：[1]广东省农垦中心医院肿瘤放疗一区,广东湛江524002

出　　处：《广东医科大学学报》2021年第4期418-421,共4页Journal of Guangdong Medical University

基　　金：湛江市非资助科技攻关计划项目(No.2019B01131)。

摘　　要：目的对比洛铂与顺铂同步放射治疗ⅡB-ⅣA期宫颈癌的疗效及毒副反应。方法选取病理学确诊且未经放化疗的宫颈癌患者60例,分为洛铂组和顺铂组,每组30例。其中洛铂组接受洛铂方案同步放化疗,顺铂组接受顺铂方案同步放化疗,比较两组的疗效和毒副反应。结果两组疗效比较差异无统计学意义(P>0.05)。洛铂组患者恶心呕吐和肾功能损害的发生率低于顺铂组(P<0.01)。结论洛铂联合同步放射治疗宫颈癌在不降低治疗效果的前提下其毒副反应比顺铂小。Objective To compare the efficacy and toxicity in lobaplatin-based and cisplatin-based concurrent chemoradiotherapy for Stage ⅡB-ⅣA cervical cancer. Methods A total of 60 patients with Stage ⅡB-ⅣA cervical cancer who had not received chemoradiotherapy were randomly divided into the Cisplatin Group and Lobaplatin Group, 30 cases in each group. The Lobaplatin Group received the lobaplatin-based concurrent chemoradiotherapy while the Cisplatin Group received the cisplatin-based concurrent chemoradiotherapy, and the two groups were compared in terms of the efficacy and toxicity. Results There was no statistical difference in the efficacy between the two groups(P>0.05). The Lobaplatin Group had the incidence of nausea, vomiting and renal impairment lower than the Cisplatin Group(P<0.01). Conclusion Lobaplatin-based concurrent chemoradiotherapy for cervical cancer has lower toxicity than cisplatin-based concurrent chemoradiotherapy without reducing the therapeutic effect.

关 键 词：洛铂 顺铂 宫颈癌 放疗 

分 类 号：R737[医药卫生—肿瘤]